导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 12.48% | 563/4773 |
| 近一周 | -3.87% | 4657/5462 |
| 近一月 | -9.20% | 4629/5421 |
| 近一季 | -12.97% | 3916/5209 |
| 近半年 | 10.72% | 450/4920 |
| 近一年 | 15.39% | 682/4366 |
| 近两年 | 170.40% | 117/2954 |
| 近三年 | 124.42% | 53/2253 |
| 成立以来 | 47.33% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.04% 3500/4961 |
53.36% 519/5312 |
- - |
- - |
| 2025 | 69.92% 129/4813 |
5.60% 759/3635 |
2.47% 1545/4076 |
63.96% 53/4524 |
-4.23% 3422/4813 |
| 2024 | 19.32% 531/3463 |
-0.95% 1156/2808 |
-3.59% 1395/3014 |
15.43% 1716/3129 |
8.24% 414/3463 |
| 2023 | 9.01% 121/2656 |
37.66% 40/2280 |
-2.24% 572/2385 |
-15.80% 2235/2515 |
-3.81% 791/2655 |
| 2022 | -35.38% 1726/2207 |
-22.71% 1710/1919 |
-2.90% 1791/2016 |
-19.14% 1756/2113 |
6.49% 362/2208 |
| 2021 | 5.24% 552/1822 |
-6.64% 1026/1255 |
15.32% 229/1330 |
-10.00% 1203/1466 |
8.62% 146/1822 |
| 2020 | - - |
- - |
- - |
-4.31% 1102/1164 |
-1.07% 1092/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华富中证人工智能产业ETF联接A VS. 长安沪深300非周期A(740101) |